Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial

Alexander Waits, Jau Yuan Chen, Wei Hong Cheng, Jih I. Yeh, Szu Min Hsieh, Charles Chen, Robert Janssen, Chia En Lien*, Tzou Yien Lin*

*Corresponding author for this work

Research output: Contribution to journalJournal Article peer-review

5 Scopus citations


Introduction: Older adults are subject to higher COVID-19 infection and mortality rates. Safety and immunogenicity of MVC-COV1901, a protein subunit vaccine have been demonstrated in phase 2 clinical trial for the general population, and negative correlations have been observed between immune responses and age, however, older adults were under-represented. Methods: A double-blind, randomized, multi-center study compared safety and immunogenicity of high-dose (25 mcg) to mid-dose (15 mcg) of MVC-COV1901 administered 2 times 28 days apart in 420 participants of 65 years and older. The results have been stratified by the comorbidity status. Results: Both high and mid-dose regimens elicited mostly mild adverse events and robust immune responses when measured as neutralizing and binding antibodies titers. High doses elicited better immune responses in the group without comorbidities. Conclusion: Given the general population-associated safety and immunogenicity of MVC-COV1901, we recommend high dose for immunization of elder adults with MVC-COV1901. The clinical trial was registered at (NCT04822025).

Original languageEnglish
Pages (from-to)21-26
Number of pages6
JournalInternational Journal of Infectious Diseases
StatePublished - 11 2022
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2022 The Author(s)


  • Immunogenicity
  • Immunosenescence
  • MVC-COV1901 vaccine
  • Older adults
  • SARS-Cov-2


Dive into the research topics of 'Safety and immunogenicity of MVC-COV1901 vaccine in older adults: Phase 2 randomized dose-comparison trial'. Together they form a unique fingerprint.

Cite this